H.C. Wainwright lowered the firm’s price target on Instil Bio (TIL) to $110 from $120 and keeps a Buy rating on the shares post the Q3 report. The firm says BioNTech’s $950M acquisition of Biotheus highlights the value potential for Instil Bio.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TIL: